CoChat

Is It the Twilight of BACE1 Inhibitors?

Open access
Hrabinova, Martina, Pejchal, Jaroslav, Kucera, Tomas, Jun, Daniel, Schmidt, Monika, Soukup, Ondrej · 2020 · Current Neuropharmacology

The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.

Abstract

: β-secretase (BACE1) has been regarded as a prime target for the development of amyloid beta (Aβ) lowering drugs in the therapy of Alzheimer´s disease (AD). Although the enzyme was discovered in 1991 and helped to formulate the Aβ hypothesis as one of the very important features of AD etiopathogenesis, progress in AD treatment utilizing BACE1 inhibitors has remained limited. Moreover, in the last years, major pharmaceutical companies have discontinued clinical trials of five BACE1 inhibitors that had been strongly perceived as prospective. In our review, the Aβ hypothesis, the enzyme, its functions, and selected substrates are described. BACE1 inhibitors are classified into four generations. Those that underwent clinical trials displayed adverse effects, including weight loss, skin rashes, worsening of neuropsychiatric symptoms, etc. Some inhibitors could not establish a statistically significant risk-benefit ratio, or even scored worse than placebo. We still believe that drugs targeting BACE1 may still hide some potential, but a different approach to BACE1 inhibition or a shift of focus to modulation of its trafficking and/or post-translational modification should now be followed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1570159x18666200503023323

Cites

198 of 198 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. (1) . Proteolytic processing of APP. (Left) Non-amyloidogenic pathway: proteolytic cleavage by α- and γ-secretases precludes amyloid β (Aβ) generation. This pathway is initiated by α-secretase and produces the soluble amino-terminal ectodomain of amyloid precursor protein (sAPPα) and the α-carboxyl-terminal fragment C83. C83 can be further cleaved by γ-secretase, producing the short fragment P3, also known as amyloid β (peptide Aβ17–40/42) and APP intracellular domain (AICD). (Right) Amyloidogenic pathway: sequential proteolytic cleavage through β- and γ-secretases is responsible for the generation of Aβ. β-secretase produces the secreted sAPPβ and the β-carboxyl-terminal fragment C99. C99 can be cleaved by γ-secretase, giving rise to Aβ and AICD. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Fig. (1) . Proteolytic processing of APP. (Left) Non-amyloidogenic pathway: proteolytic cleavage by α- and γ-secretases precludes amyloid β (Aβ) generation. This pathway is initiated by α-secretase and produces the soluble amino-terminal ectodomain of amyloid precursor protein (sAPPα) and the α-carboxyl-terminal fragment C83. C83 can be further cleaved by γ-secretase, producing the short fragment P3, also known as amyloid β (peptide Aβ17–40/42) and APP intracellular domain (AICD). (Right) Amyloidogenic pathway: sequential proteolytic cleavage through β- and γ-secretases is responsible for the generation of Aβ. β-secretase produces the secreted sAPPβ and the β-carboxyl-terminal fragment C99. C99 can be cleaved by γ-secretase, giving rise to Aβ and AICD. (A higher resolution / colour version of this figure is available in the electronic copy of the article).CC BY-NC · PubMed Central
Fig. (2) Structural organization of BACE1. SP - signal peptide, PD - prodomain, CaD - catalytic domain, TD - transmembrane domain, CD - cytoplasmatic domain, DTGS and DSGT - active sites. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Fig. (2) Structural organization of BACE1. SP - signal peptide, PD - prodomain, CaD - catalytic domain, TD - transmembrane domain, CD - cytoplasmatic domain, DTGS and DSGT - active sites. (A higher resolution / colour version of this figure is available in the electronic copy of the article).CC BY-NC · PubMed Central
Fig. (3) Trafficking of BACE1. (1) In the endoplasmic reticulum, BACE1 is initially synthesized as a zymogen and subjected to N-glycosylation, palmitoylation, transient acetylation, and disulfide bridge formation. (2) Full maturation takes place in the Golgi compartment, where complex glycosylation and removal of the prodomain by furin prohormone protein convertases lead to the 75 kDa form. (3) Newly synthesized BACE1 is transported from the trans-Golgi network (TGN) to the cytoplasmic membrane (CM). (4) BACE1 can be reinternalized from CM to endosomes. (5) BACE1 binds with GGA1 via an acid-cluster-dileucine (ACDL) motif. The binding regulates the transport of enzymes from endosomes to TGN. (6) Amyloid precursor protein (APP) is cleaved by BACE1 in the endosomes, producing amyloid β (Aβ). (7) Phosphorylation at ser498 regulates BACE1 trafficking. Phosphorylated BACE1 is intercepted from the cell surface to early endosomes. The non-phosphorylated BACE1 recycles back to CM. (8) Lastly, mono-ubiquitination at lysine 501 and binding with GGA3 promote lysosomal degradation. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Fig. (3) Trafficking of BACE1. (1) In the endoplasmic reticulum, BACE1 is initially synthesized as a zymogen and subjected to N-glycosylation, palmitoylation, transient acetylation, and disulfide bridge formation. (2) Full maturation takes place in the Golgi compartment, where complex glycosylation and removal of the prodomain by furin prohormone protein convertases lead to the 75 kDa form. (3) Newly synthesized BACE1 is transported from the trans-Golgi network (TGN) to the cytoplasmic membrane (CM). (4) BACE1 can be reinternalized from CM to endosomes. (5) BACE1 binds with GGA1 via an acid-cluster-dileucine (ACDL) motif. The binding regulates the transport of enzymes from endosomes to TGN. (6) Amyloid precursor protein (APP) is cleaved by BACE1 in the endosomes, producing amyloid β (Aβ). (7) Phosphorylation at ser498 regulates BACE1 trafficking. Phosphorylated BACE1 is intercepted from the cell surface to early endosomes. The non-phosphorylated BACE1 recycles back to CM. (8) Lastly, mono-ubiquitination at lysine 501 and binding with GGA3 promote lysosomal degradation. (A higher resolution / colour version of this figure is available in the electronic copy of the article).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 198 references

Research works printed but not linked: 1

  1. McElrath K.J.; Why has pfizer discontinued research on neurodegenerative diseases? [Apr 15, 2020];

Cited by

See all 28

Metadata

Authors
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O.
Affiliations
  • Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Hradec Kralove, Czech Republic
  • University of Defence (CZ)
  • University Hospital Hradec Králové (CZ)
Corresponding author
Pejchal, Jaroslav
Venue
Current Neuropharmacology
Published
2020-12-31
Volume
19
Issue
1
Pages
61-77
ISSN
1570-159X (ISSN-L)
OpenAlex
W3022006874
Cited by
28
References
198
Citations by year
2026: 4 · 2025: 6 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 1
FWCI
2.10
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Current Neuropharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
BACE1 inhibitors, beta-secretase, Alzheimer's disease, clinical trial discontinuation, adverse drug reactions, post-translational modification, risk-benefit ratio
MeSH terms
Alzheimer Disease, Humans, Prospective Studies, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is It the Twilight of BACE1 Inhibitors? https://app.cochat.ai/papers/10.2174/1570159x18666200503023323
The paper
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020). Is It the Twilight of BACE1 Inhibitors? Current Neuropharmacology. https://doi.org/10.2174/1570159x18666200503023323

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.